FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jean-Pascal Machiels

Research Profile

Chemicals & Drugs

Disorders

Mammary Neoplasms, Experimental

Genes & Molecular Sequences

Genes, erbB-2

Living Beings

Anatomy

Physiology

Procedures

Concepts & Ideas

T-Lymphocyte Subsets

Co-author Network

Publications

TOP 3
Siwen Hu-Lieskovan; Melissa J Labonte; Dirk Arnold; Matej Bračko; Annelies Debucquoy; Kathrin Dellas; Peter P Grimminger; Karin Haustermans; Arnulf H Hölscher; Jean-Pascal H Machiels; Alexander Pohl; Claus Rödel; Christine Sempoux; Robert Semrau; Daniel Vallbohmer; Vaneja Velenik; Dongyun Yang; Wu Zhang; Heinz-Josef Lenz
EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.
Thomas E Hutson; Ian D Davis; Jean-Pascal H Machiels; Paul L De Souza; Sylvie Rottey; Bao-fa Hong; Richard J Epstein; Katherine L Baker; Lauren McCann; Theresa Crofts; Lini Pandite; Robert A Figlin
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
Jean-Pascal H Machiels; Stéphanie Henry; Sylvie Zanetta; Marie-Christine Kaminsky; N Michoux; Denis Rommel; Sandra Schmitz; Emmanuelle Bompas; Anne-Françoise Dillies; Sandrine Faivre; Anne Moxhon; Thierry Duprez; Joel Guigay
Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jean-Pascal Machiels (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Siwen Hu-Lieskovan; Melissa J Labonte; Dirk Arnold; Matej Bračko; Annelies Debucquoy; Kathrin Dellas; Peter P Grimminger; Karin Haustermans; Arnulf H Hölscher; Jean-Pascal H Machiels; Alexander Pohl; Claus Rödel; Christine Sempoux; Robert Semrau; Daniel Vallbohmer; Vaneja Velenik; Dongyun Yang; Wu Zhang; Heinz-Josef Lenz
EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(15):5161-9.
2010: Thomas E Hutson; Ian D Davis; Jean-Pascal H Machiels; Paul L De Souza; Sylvie Rottey; Bao-fa Hong; Richard J Epstein; Katherine L Baker; Lauren McCann; Theresa Crofts; Lini Pandite; Robert A Figlin
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(3):475-80.
2010: Jean-Pascal H Machiels; Stéphanie Henry; Sylvie Zanetta; Marie-Christine Kaminsky; N Michoux; Denis Rommel; Sandra Schmitz; Emmanuelle Bompas; Anne-Françoise Dillies; Sandrine Faivre; Anne Moxhon; Thierry Duprez; Joel Guigay
Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(1):21-8.
2009: Christian Wülfing; Jean-Pascal H Machiels; Dirk J Richel; Marc-Oliver Grimm; Uwe Treiber; Marco R De Groot; Philippe Beuzeboc; Roma Parikh; Frank Pétavy; Iman A El-Hariry
A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.
Cancer 2009;115(13):2881-90.
2005: Anne M Ercolini; Brian H Ladle; Elizabeth A Manning; Lukas W Pfannenstiel; TD Armstrong; Jean-Pascal H Machiels; Joan G Bieler; Leisha A Emens; Richard T. Reilly; Elizabeth M Jaffee
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.
The Journal of experimental medicine 2005;201(10):1591-602.
2003: Anne M Ercolini; Jean-Pascal H Machiels; Yi Cheng Chen; Jill E Slansky; Martin Giedlen; Richard T. Reilly; Elizabeth M Jaffee
Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(8):4273-80.
2002: Richard T. Reilly; Jean-Pascal H Machiels; Leisha A Emens; Elizabeth M Jaffee
Cytokine gene-modified cell-based cancer vaccines.
Methods in molecular medicine 2002;69():233-57.
2001: Jean-Pascal H Machiels; Richard T. Reilly; Leisha A Emens; Anne M Ercolini; RY Lei; D Weintraub; FI Okoye; Elizabeth M Jaffee
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
Cancer research 2001;61(9):3689-97.
2001: Leisha A Emens; Jean-Pascal H Machiels; Richard T. Reilly; Elizabeth M Jaffee
Chemotherapy: friend or foe to cancer vaccines?
Current opinion in molecular therapeutics 2001;3(1):77-84.
2001: Richard T. Reilly; Jean-Pascal H Machiels; Leisha A Emens; Anne M Ercolini; FI Okoye; RY Lei; D Weintraub; Elizabeth M Jaffee
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Cancer research 2001;61(3):880-3.
2000: Richard T. Reilly; M B Gottlieb; Anne M Ercolini; Jean-Pascal H Machiels; C E Kane; FI Okoye; W J Muller; K H Dixon; Elizabeth M Jaffee
HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
Cancer research 2000;60(13):3569-76.